Advertisement
NGNE vs RNAZ
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a StrongBuy and RNAZ is a StrongBuy.
NGNE sees its Stochastic Oscillator recovers from oversold territory
On October 19, 2026, the Stochastic Oscillator for NGNE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In 57 of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NGNE's RSI Oscillator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NGNE as a result. In 77 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for NGNE just turned positive on October 20, 2026. Looking at past instances where NGNE's MACD turned positive, the stock continued to rise in 39 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where NGNE advanced for three days, in 237 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NGNE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for NGNE crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGNE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NGNE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.404) is normal, around the industry mean (2.988). P/E Ratio (-5.175) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (416.667) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NGNE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGNE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RNAZ in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 01, 2026
RNAZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 42 cases where RNAZ's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNAZ's RSI Indicator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAZ advanced for three days, in 158 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNAZ as a result. In 77 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RNAZ entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.015) is normal, around the industry mean (2.988). P/E Ratio (-0.034) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. RNAZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NGNE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 78 | |
P/E GROWTH RATING 1..100 | 16 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| NGNE | RNAZ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | N/A |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 85% | 8 days ago 79% |
| Declines ODDS (%) | 10 days ago 87% | 15 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NGNE’s FA Score shows that 1 FA rating(s) are green while RNAZ’s FA Score has 2 green FA rating(s).
- NGNE’s FA Score: 1 green, 4 red.
- RNAZ’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NGNE’s TA Score shows that 6 TA indicator(s) are bullish while RNAZ’s TA Score has 4 bullish TA indicator(s).
- NGNE’s TA Score: 6 bullish, 3 bearish.
- RNAZ’s TA Score: 4 bullish, 3 bearish.
Price Growth
NGNE (@Biotechnology) experienced а +17.58% price change this week, while RNAZ (@Biotechnology) price change was -4.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
NGNE is expected to report earnings on Nov 12, 2026.
RNAZ is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NGNE and
Correlation & Price change
A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with RCKT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then RCKT could also see price increases.
| Ticker / NAME | Correlation To NGNE | 1D Price Change % | ||
|---|---|---|---|---|
| NGNE | 100% | +2.68% | ||
| RCKT - NGNE | 52% Loosely correlated | -5.98% | ||
| BRNS - NGNE | 51% Loosely correlated | N/A | ||
| TSHA - NGNE | 49% Loosely correlated | +0.24% | ||
| RNAZ - NGNE | 48% Loosely correlated | N/A | ||
| BCYC - NGNE | 45% Loosely correlated | -0.83% | ||
More | ||||
RNAZ and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNAZ has been loosely correlated with NGNE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RNAZ jumps, then NGNE could also see price increases.
| Ticker / NAME | Correlation To RNAZ | 1D Price Change % | ||
|---|---|---|---|---|
| RNAZ | 100% | N/A | ||
| NGNE - RNAZ | 48% Loosely correlated | +2.68% | ||
| AEON - RNAZ | 38% Loosely correlated | +3.76% | ||
| AGEN - RNAZ | 32% Poorly correlated | -0.31% | ||
| JAGX - RNAZ | 31% Poorly correlated | -13.31% | ||
| EDSA - RNAZ | 31% Poorly correlated | +1.06% | ||
More | ||||